Akin C, Arock M, Carter MC, George TI, Valent P, Mastocytosis (2025) Nat Rev Dis Primers 11(1):30

Article  PubMed  Google Scholar 

Brockow K, Jofer C, Behrendt H, Ring J (2008) Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 63(2):226–232

Article  CAS  PubMed  Google Scholar 

Castells M, Butterfield J (2019) Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract 7(4):1097–1106

Article  PubMed  Google Scholar 

Jendoubi F, Gaudenzio N, Gallini A, Negretto M, Paul C, Bulai Livideanu C (2020) Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy 50(6):654–661

Article  CAS  PubMed  Google Scholar 

Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S et al (2023) Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid 2(6):EVIDoa2200339

Article  PubMed  Google Scholar 

Bergmann L, Mittrou P (1985) Recombinant gamma-interferon in the treatment of a patient with malignant mastocytosis. Blut 51:218

Google Scholar 

Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM et al (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326(9):619–623

Article  CAS  PubMed  Google Scholar 

Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD (1996) Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 22(5–6):501–508

Article  CAS  PubMed  Google Scholar 

Butterfield JH (1998) Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 138(3):489–495

Article  CAS  PubMed  Google Scholar 

Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M (1991) Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol 85(4):220

Article  CAS  PubMed  Google Scholar 

Schernthaner GH, Spanblöchl E, Sperr WR, Sillaber C, Semper H, Jurecka W et al (2000) Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol 79(12):660–6

Article  CAS  PubMed  Google Scholar 

Kobayashi T, Shimabukuro-Demoto S, Tsutsui H, Toyama-Sorimachi N (2019) Type i interferon limits mast cell-mediated anaphylaxis by controlling secretory granule homeostasis. PLoS Biol 17(11):e3000530

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saven A, Burian C (1999) Cladribine activity in adult langerhans-cell histiocytosis. Blood 93(12):4125–4130

Article  CAS  PubMed  Google Scholar 

Lübke J, Naumann N, Metzgeroth G, Kreil S, Brand T, Horny HP et al (2023) Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis. Ann Hematol 102(8):2077–85

Article  PubMed  PubMed Central  Google Scholar 

Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van ’t Wout JW, Verhoef G, Gerrits WBJ et al (2003) Cladribine therapy for systemic mastocytosis. Blood 102(13):4270–4276

Article  CAS  PubMed  Google Scholar 

Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A (2004) Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 28(2):127–131

Article  CAS  PubMed  Google Scholar 

Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P (2012) Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 157(4):399–405

Article  CAS  PubMed  Google Scholar 

Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C et al (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 126(8):1009–1016 quiz 1050

Article  CAS  PubMed  Google Scholar 

Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K et al (2010) In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 38(9):744–55

Article  PubMed  Google Scholar 

Piris-Villaespesa M, Alvarez-Twose I (2020) Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol 11:443

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carpio-Escalona LV, Prieto-García A, Morales-Cabeza C, Guilarte M, Matito A, Torrado I et al (2025) Tyrosine kinase inhibitors for the treatment of mast cell diseases: review and update. J Investig Allergol Clin Immunol 35(5):328–340

Article  CAS  PubMed  Google Scholar 

Verstovsek S, Tefferi A, Cortes J, O’Brien S, Garcia-Manero G, Pardanani A et al (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14(12):3906–3915

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R et al (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33(11):1481–4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C et al (2008) The effects of dasatinib on IgE receptor-dependent activation and Histamine release in human basophils. Blood 111(6):3097–3107

Article  CAS  PubMed  Google Scholar 

Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L et al (2015) Long-term treatment with Imatinib results in profound mast cell deficiency in Ph + chronic myeloid leukemia. Oncotarget 6(5):3071–3084

Article  PubMed  PubMed Central  Google Scholar 

Gotlib J, Kluin-Nelemans HC, Akin C, Hartmann K, Valent P, Reiter A (2021) Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther 21(4):487–498

Article  PubMed  Google Scholar 

Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374(26):2530–2541

Article  CAS  PubMed  Google Scholar 

DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J et al (2018) Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 32(2):470–478

Article  CAS  PubMed  Google Scholar 

Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E et al (2020) Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol 146(2):356-366.e4

Article  CAS  PubMed  Google Scholar 

van Anrooij B, Oude Elberink JNG, Span LFR, de Monchy JGR, Rosati S, Mulder AB et al (2018) Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial. J Allergy Clin Immunol 142(3):1006-1008.e7

Article  PubMed  Google Scholar 

DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW et al (2021) Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 27(12):2183–2191

Article  CAS  PubMed  PubMed Central